NasdaqGS - Delayed Quote USD
Spyre Therapeutics, Inc. (SYRE)
17.16
+0.19
+(1.12%)
At close: June 9 at 4:00:01 PM EDT
18.11
+0.95
+(5.54%)
Pre-Market: 8:26:00 AM EDT
Insider Purchases Last 6 Months
| Shares | Transactions | |
|---|---|---|
| Purchases | 0 | 0 |
| Sales | -- | 0 |
| Net Shares Purchased (Sold) | 0 | 0 |
| Total Insider Shares Held | 5.26M | -- |
| % Net Shares Purchased (Sold) | -- | -- |
Net Institutional Purchases Prior Quarter to Latest Quarter
| Shares | |
|---|---|
| Net Shares Purchased (Sold) | -- |
| % Change in Institutional Shares Held | -- |
Insider Transactions Reported - Last Two Years
| Insider | Transaction | Type | Value | Date |
|---|---|---|---|---|
| ALBERS JEFFREY W Director | Sale at price 36.76 per share. | Indirect | 246,313 | Nov 6, 2024 |
| ALBERS JEFFREY W Director | Sale at price 36.43 per share. | Indirect | 10,929 | Oct 25, 2024 |
| BURROWS SCOTT L. Chief Financial Officer | Sale at price 28.17 per share. | Direct | 522,074 | Sep 3, 2024 |
| FAIRMOUNT FUNDS MANAGEMENT LLC Beneficial Owner of more than 10% of a Class of Security | -- | Indirect | -- | Apr 25, 2024 |
| TURTLE CAMERON Chief Executive Officer | Stock Award(Grant) at price 22.56 per share. | Direct | 9,024 | Feb 15, 2024 |
| BURROWS SCOTT L. Chief Financial Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Dec 22, 2023 |
| ALBERS JEFFREY W Director | -- | Indirect | -- | Nov 24, 2023 |
| TURTLE CAMERON Chief Executive Officer | -- | Direct | -- | Nov 24, 2023 |
| FAIRMOUNT FUNDS MANAGEMENT LLC Beneficial Owner of more than 10% of a Class of Security | -- | Indirect | -- | Nov 24, 2023 |
| SOUZA MARCIO SILVA DE Director | Purchase at price 0.56 per share. | Direct | 50,472 | Aug 25, 2022 |
| HANLEY MICHAEL CONICK JR. Officer | Purchase at price 0.71 per share. | Direct | 20,022 | Jun 8, 2022 |
| QUINN ANTHONY G Chief Executive Officer | Purchase at price 2.34 per share. | Direct | 187,705 | Mar 16, 2022 |
| QUINN ANTHONY G Chief Executive Officer | Purchase at price 1.86 - 2.06 per share. | Direct | 280,943 | Mar 15, 2022 |
| ALSPAUGH JONATHAN D. Chief Financial Officer | Purchase at price 2.08 per share. | Direct | 156,000 | Mar 11, 2022 |
| SHANAFELT ARMEN B Director | Purchase at price 3.65 - 3.67 per share. | Direct | 549,692 | Dec 13, 2021 |
| QUINN ANTHONY G Chief Executive Officer | Purchase at price 3.70 - 3.75 per share. | Direct | 198,972 | Dec 10, 2021 |
| ALSPAUGH JONATHAN D. Chief Financial Officer | Purchase at price 3.72 per share. | Direct | 186,000 | Dec 9, 2021 |
| QUINN ANTHONY G Chief Executive Officer | Stock Gift at price 0.00 per share. | Direct | 0 | Oct 20, 2021 |
| ALSPAUGH JONATHAN D. Chief Financial Officer | Purchase at price 6.37 - 6.72 per share. | Direct | 262,660 | Aug 18, 2021 |
| QUINN ANTHONY G Chief Executive Officer | Purchase at price 7.77 per share. | Direct | 1,282,050 | Apr 30, 2020 |
| QUINN ANTHONY G Chief Executive Officer | Conversion of Exercise of derivative security at price 5.46 - 6.31 per share. | Direct | 114,689 | Oct 4, 2019 |
| QUINN ANTHONY G Chief Executive Officer | Purchase at price 6.11 - 6.23 per share. | Direct | 196,453 | Jun 14, 2019 |
| QUINN ANTHONY G Chief Executive Officer | Purchase at price 6.55 - 6.89 per share. | Direct | 180,032 | May 22, 2019 |
| QUINN ANTHONY G Chief Executive Officer | Purchase at price 6.65 - 7.10 per share. | Direct | 126,399 | May 17, 2019 |
| QUINN ANTHONY G Chief Executive Officer | Conversion of Exercise of derivative security at price 5.46 - 6.31 per share. | Direct | 54,126 | Feb 6, 2019 |
| QUINN ANTHONY G Chief Executive Officer | Conversion of Exercise of derivative security at price 4.11 - 6.31 per share. | Direct | 751,816 | Dec 7, 2018 |
| SCHUCHART AARON Officer | Sale at price 9.50 - 9.55 per share. | Direct | 57,005 | Sep 27, 2018 |
| SCHUCHART AARON Officer | Conversion of Exercise of derivative security at price 3.50 per share. | Direct | 29,750 | Aug 17, 2018 |
| QUINN ANTHONY G Chief Executive Officer | Purchase at price 6.02 - 9.13 per share. | Direct | 21,115 | Aug 15, 2018 |
| GEORGIOU GEORGE Director | Conversion of Exercise of derivative security at price 4.73 - 7.28 per share. | Direct | 220,784 | Aug 13, 2018 |
| QUINN ANTHONY G Chief Executive Officer | Conversion of Exercise of derivative security at price 6.31 - 7.04 per share. | Direct | 262,764 | Jul 12, 2018 |
| QUINN ANTHONY G Chief Executive Officer | Conversion of Exercise of derivative security at price 5.46 per share. | Direct | 18,056 | Jul 11, 2018 |
| NOVARTIS BIOVENTURES, LTD. Beneficial Owner of more than 10% of a Class of Security | Sale at price 10.06 per share. | Indirect | 196,673 | May 11, 2018 |
| NOVARTIS BIOVENTURES, LTD. Beneficial Owner of more than 10% of a Class of Security | Sale at price 10.11 - 10.13 per share. | Indirect | 748,140 | May 10, 2018 |
| NOVARTIS BIOVENTURES, LTD. Beneficial Owner of more than 10% of a Class of Security | Sale at price 10.03 - 10.11 per share. | Direct | 423,557 | May 8, 2018 |
| QUINN ANTHONY G Chief Executive Officer | Conversion of Exercise of derivative security at price 5.46 per share. | Direct | 83,052 | Feb 15, 2018 |
| QUINN ANTHONY G Chief Executive Officer | Purchase at price 4.92 - 5.07 per share. | Direct | 41,078 | Dec 8, 2017 |
| QUINN ANTHONY G Director | Purchase at price 4.53 - 4.98 per share. | Direct | 83,177 | Dec 5, 2017 |
| YORK CHARLES N. II CPA Chief Financial Officer | Purchase at price 2.52 - 4.97 per share. | Direct | 116,223 | Dec 5, 2017 |
| ORBIMED ADVISORS, L.L.C. Beneficial Owner of more than 10% of a Class of Security | Purchase at price 5.04 - 5.36 per share. | Indirect | 563,882 | Feb 21, 2017 |
| ELI LILLY & CO Beneficial Owner of more than 10% of a Class of Security | Purchase at price 10.00 per share. | Indirect | 5,000,000 | Apr 12, 2016 |
| ELI LILLY & CO Beneficial Owner of more than 10% of a Class of Security | -- | Indirect | -- | Apr 12, 2016 |
| TYLER JOSEPH E Officer | -- | Direct | -- | Apr 12, 2016 |
| NOVARTIS BIOVENTURES, LTD. Beneficial Owner of more than 10% of a Class of Security | Purchase at price 10.00 per share. | Indirect | 3,000,000 | Apr 12, 2016 |
| NOVARTIS BIOVENTURES, LTD. Beneficial Owner of more than 10% of a Class of Security | -- | Indirect | -- | Apr 12, 2016 |
| LOWE DAVID GEORGE Chief Executive Officer | -- | Indirect | -- | Apr 12, 2016 |
| COX RUSSELL J Director | Purchase at price 10.00 per share. | Direct | 70,000 | Apr 12, 2016 |
| QUINN ANTHONY G Director | Purchase at price 10.00 per share. | Direct | 100,000 | Apr 12, 2016 |
| YORK CHARLES N. II CPA Chief Financial Officer | -- | Indirect | -- | Apr 12, 2016 |
| ROWLINSON SCOTT W Officer | -- | Indirect | -- | Apr 12, 2016 |
Related Tickers
ORKA Oruka Therapeutics, Inc.
12.54
-0.32%
APGE Apogee Therapeutics, Inc.
40.13
-2.07%
CNTA Centessa Pharmaceuticals plc
11.94
+0.17%
XNCR Xencor, Inc.
9.55
-1.04%
CRNX Crinetics Pharmaceuticals, Inc.
32.28
-2.21%
JBIO Jade Biosciences, Inc.
7.71
+7.23%
XENE Xenon Pharmaceuticals Inc.
31.45
-0.60%
UPB Upstream Bio, Inc.
11.29
+0.18%
SION Sionna Therapeutics, Inc.
16.46
-4.41%
DSGN Design Therapeutics, Inc.
3.9100
-2.49%